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Previewsmetaplasia (ADM) do, indeed, harbor
KRAS mutations identical to those ob-
served in adjacent PanIN (Shi et al.,
2009). These findings might be consistent
with KRAS mutations arising in either
acinar cells themselves or in areas of
ADM, with subsequent rapid progression
to PanIN.
Assuming that these findings are
indeed relevant to the human disease,
what are the ramifications of the current
findings? Certainly, they suggest that
future chemoprevention strategies might
be best targeted at early events in acinar
rather than ductal cells; blocking acinar
cell activation of Sox9 now joins Notch
pathway inhibition and maintenance of
Mist1 expression as examples of such
approaches. In addition, these findings
underscore an increasingly recognized
disconnect between Kras mutations and
Kras activity. Along these lines, it will be
fascinating to determine the presumably
epigenetic determinants underlying the
differential responsiveness to oncogenicKras observed in acinar and ductal cell
types; manipulating such determinants
may convert acinar cells into less capable
parents, hopefully eliminating PanIN from
the pancreatic family tree.REFERENCES
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Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these
agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance
to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.More than 25 years have passed since the
discovery of phosphoinositide 3-kinase
(PI3K) as an oncoprotein-associated
enzymatic activity. The term ‘‘PI3K’’ in
this context designates the Class I subset
of phosphoinositide kinases (comprising
the a, b, g, and d isoforms), which convert
phosphatidylinositol-4,5-bisphosphate to
the bioactive second messenger phos-
phatidylinositol-3,4,5-trisphosphate (Van-
haesebroeck et al., 2012). These PI3Ksare activated, directly or indirectly, by
a variety of cell surface receptors that
include receptor tyrosine kinases (RTKs)
and G protein-coupled receptors. Several
cardinal alterations elicited by PI3K acti-
vation include changes in cell prolifera-
tion, survival, migration, and metabolism,
and are highly aligned with the ‘‘hallmarks
of cancer’’ discussed by Hanahan and
Weinberg (2011). Indeed, inappropriate
activation of the PI3K pathway has beenobserved in a remarkably broad array of
human cancers. Nested within this pro-
oncogenic signaling network are two
pivotal protein serine-threonine kinases,
AKT (also termed protein kinase B) and
mTOR, both of which represent druggable
targets, like PI3K itself. This combination
of biological relevance and pharmaco-
logical tractability rendered the PI3K
pathway an irresistible target for cancer
drug discovery. The ensuing efforts inecember 11, 2012 ª2012 Elsevier Inc. 703
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Previewsmedicinal chemistry delivered a treasure
trove of PI3K pathway inhibitors, and a
stunning number (25–30) of these
compounds are now in various stages of
late preclinical or clinical development.
The unprecedented level of pharma-
ceutical investment in PI3K pathway
inhibitors was based on expectations
that these agents would exert broad-
based inhibitory effects on tumor growth
and progression. Unfortunately, single-
agent therapy with PI3K pathway inhibi-
tors has, with few exceptions, failed to
deliver on the promise of breakthrough
antitumor activity in the clinical setting.
Adaptive drug resistance has emerged
as an important mechanism whereby
cancer cells limit the therapeutic activities
of these inhibitors (Bagrodia et al.,
2012). Recent studies indicate that phar-
macological disruption of PI3K signaling
engages a multiplicity of compensatory
responses that restore signal flux to a level
that maintains the oncogenic phenotype.
An intriguing report by Britschgi et al.
(2012) in this issue of Cancer Cell
adds to this compendium of resistance
mechanisms by demonstrating that
certain tumors acquire resistance to
PI3K pathway-targeted therapies by elab-
orating a pro-inflammatory chemokine
that not only drives drug resistance, but
also leads to a more invasive, metastatic
phenotype for the cancer cells.
Britschgi et al. (2012) focused their
studies on triple-negative breast cancer
(TNBC), a tumor type differentiated from
other breast cancer subtypes by the
absence of receptors for HER2, proges-
terone, and estrogen. TNBC is a highly
aggressive disease with a poor response
to current therapies. Evidence that the
PI3K pathway is commonly activated in
TNBC has raised hope that PI3K
pathway-targeted agents might signifi-
cantly alter the therapeutic landscape
for this disease (Ibrahim et al., 2012).
Britschgi et al. (2012) examined the phos-
phorylation states of specific signaling
proteins during acute (%20 hr) exposure
of TNBC-like cell lines to BEZ235,
a dually-active PI3K/mTOR inhibitor. An
unanticipated finding was that BEZ235
exposure stimulated tyrosine phos-
phorylation of the JAK2 kinase and its
substrate, the STAT5 transcription factor.
The JAK kinase family consists of four
members, which are typically (but not
exclusively) activated by cytokine and704 Cancer Cell 22, December 11, 2012 ª20chemokine receptors (Seavey and Dobr-
zanski, 2012). The activated JAKs, in
turn, phosphorylate one or more of the
seven STAT family proteins, thereby stim-
ulating their nuclear translocation and
transactivating functions. BEZ235 treat-
ment triggered selective modification
of JAK2 and STAT5, indicating that
this drug provoked specific rather gener-
alized activation of JAK-STAT signaling
in these TNBC cell lines (Britschgi et al.,
2012). Further experiments revealed that
BEZ235 stimulated the expression of
mRNA transcripts encoding interleukin-8
(IL-8) and the subsequent secretion of
this chemokine by the drug-treated cells.
The expression of IL-8 receptor CXCR1
was also increased during BEZ235
exposure, establishing an autokine-acting
chemokine signaling pathway in the drug-
treated TNBC cells.
Exploration of the mechanism under-
lying BEZ235-induced JAK2-STAT5 acti-
vation uncovered a biphasic response.
The early (0–8 hr after drug treatment)
increase in JAK2-STAT5 activation was
linked to upregulation of the IR/IGF-1R
signaling pathway. This finding is consis-
tent with previous observations that inhi-
bition of the PI3K-AKT axis of the PI3K
signaling network stimulates a FOXO
transcription factor-dependent homeo-
static response leading to upregulation
of receptors that strongly activate PI3K,
such as the RTKs IR/IGF1R and MET
(Chakrabarty et al., 2012; Muranen et al.,
2012). The initial wave of JAK2/STAT5
signaling stimulated the expression and
secretion of IL-8, which then acted
through the CXCR1 receptor to drive
a second wave of JAK2-STAT5 activity.
Thus, inhibition of PI3K/mTOR sets in
motion a sequence of events that culmi-
nate in a self-amplifying autocrine loop
involving the IL-8-CXCR1-JAK2-STAT5
signaling cascade. The unanticipated
increase in IL-8 signaling provoked by
PI3K/mTOR inhibition was at least
partially responsible for limiting the inhib-
itory effects of BEZ235 on AKT activity,
cancer cell survival in vitro, and tumor
growth in vivo. Moreover, these results
may have broader clinical implications,
in that IL-8 is recognized as a significant
tumor progression factor through its
pleiotropic activities related to cancer
stem cells, angiogenesis, and metastasis
(Waugh and Wilson, 2008). Hence, it is
conceivable that treatment of TNBC with12 Elsevier Inc.PI3K/mTOR inhibitors could to lead to
worsened patient outcomes related to
enhanced intratumoral IL-8 activity.
Although these findings place an addi-
tional obstacle in the path to successful
implementation of PI3K pathway-tar-
geted therapies, they also present a thera-
peutic opportunity, in that the IL8-depen-
dent adaptive response is amenable to
pharmacologic intervention (for example
with drugs that target JAK2) (Seavey and
Dobrzanski, 2012). Indeed, Britschgi
et al. (2012) demonstrated that combina-
tion therapy with a JAK2 kinase inhibitor
increased the antiproliferative and cytoci-
dal activities of BEZ235 in vitro and
augmented the antitumor activity of
BEZ235 in mouse xenograft studies.
Furthermore, the authors observed that
circulating tumor cell numbers in mice
bearing highly metastatic breast tumors,
which were only marginally reduced by
the PI3K/mTOR inhibitor, were dramati-
cally suppressed by treatment with a
JAK2 inhibitor, both in the absence and
presence of BEZ235. The authors further
noted that CXCR1 expression was
heterogeneous in these tumor cell
populations and presented evidence that
the most highly CXCR1-positive cells
were enriched for both tumor-initiating
and metastatic behaviors. The results
support a clinically testable combination
strategy involving PI3K-mTOR and JAK2
inhibitors in TNBC and in other tumors
in which suppression of PI3K signaling
provokes a compensatory increase in
IL8 production.
This study underscores the robustness
of the adaptive network that strives to
maintain homeostatic signal flux through
the PI3K pathway in cancer cells. Previ-
ously described mechanisms of PI3K
inhibitor resistance can be characterized
as ‘‘vertical’’; for example, inhibition of
PI3K-a elicits a homeostatic response,
such as increased expression of IR/
IGF1R, which aims to restore PI3K-a
activity (Figure 1). The adaptive response
uncovered by Britschgi et al. (2012) adds
a chemokine-dependent ‘‘horizontal’’
element to the existing array of PI3K inhib-
itor resistance mechanisms. The more
sobering news might be that this adaptive
response confers not only drug resis-
tance, but also a more aggressive pheno-
type on TNBC cells.
This study raises several questions for
future investigation. First, given that IL-8
Figure 1. Acquisition of Resistance to PI3K/mTOR Inhibitors through Compensatory
Activation of the JAK2-STAT5 Pathway
Triple-negative breast cancer cells drive signaling through the PI3K/mTOR pathway via activation of
receptor tyrosine kinases, such as insulin receptors and insulin-like growth factor-1 receptors (IR/IGF-
1R). Treatment with a PI3K-mTOR inhibitor triggers a biphasic adaptive resistance response. In the initial
phase of this response, the cells upregulate expression of IR/IGF-1R and IRS-1 (1), which stimulates
a compensatory increase in PI3K-a activity (vertical resistance), together with IRS-1-dependent activation
of the JAK2-STAT5 pathway (2). STAT5 translocates to the nucleus and stimulates transcription of the
genes encoding interleukin-8 (IL-8) and the IL-8 receptor, CXCR1 (3). The secretion of IL-8 establishes
a self-amplifying, autocrine and/or paracrine chemokine loop that might activate a different PI3K isoform,
PI3K-g (4), and propagates JAK2-STAT5 activation, leading to horizontal drug resistance and increased
tumorigenicity and invasiveness in TNBC cell populations (5).
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Previewssignals through a GPCR, it would be inter-
esting to learn whether the IL-8-depen-
dent adaptive response involves a switch
from PI3K-a to the GPCR-associated
PI3K-g isoform (Figure 1). Second, PI3K/
mTOR inhibitors stimulate autophagy,which was recently shown to support the
secretion of IL-8 and other pro-inflamma-
tory cytokines through an unconventional
secretory pathway (Deretic et al., 2012). If
IL-8 release from drug-treated TNBC cells
is attributable to unconventional secre-Cancer Cell 22, Dtion, then this mechanism of adaptive
resistancemight be susceptible to combi-
nation therapy with an autophagy inhib-
itor. Finally, and most importantly, we
need to understand more fully the actual
contributions of IL-8 to PI3K/mTOR inhib-
itor resistance in human TNBC patients,
as well the roles of drug-induced IL-8
release in adaptive drug resistance in
other human cancers.REFERENCES
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